Sutro Biopharma, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements and Short-Term Investments (Tables)

Fair Value Measurements and Short-Term Investments (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value of Financial Assets and Liabilities Measured on Recurring Basis

The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy:

	December 31, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market funds	$	3,151	$	3,151	$	-	$	-
Commercial paper		4,952		-		4,952		-
Corporate debt securities		69,499		-		69,499		-
Asset-backed securities		27,055		-		27,055		-
U.S. government agency securities		27,007		-		27,007		-
Total	$	131,664	$	3,151	$	128,513	$	-

	December 31, 2018
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market funds	$	116,202	$	116,202	$	-	$	-
Commercial paper		26,625		-		26,625		-
Corporate debt securities		11,774		-		11,774		-
Asset-backed securities		16,899		-		16,899		-
U.S. government agency securities		23,896		-		23,896		-
Total	$	195,396	$	116,202	$	79,194	$	-